Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Emergent Health

OTCPK:EMGE
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EMGE
OTCPK
$2M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Emergent Health Corp. develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. The last earnings update was 1883 days ago. More info.


Add to Portfolio Compare Print
EMGE Share Price and Events
7 Day Returns
-
OTCPK:EMGE
3.5%
US Biotechs
2.4%
US Market
1 Year Returns
-56%
OTCPK:EMGE
4.6%
US Biotechs
-10%
US Market
EMGE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Emergent Health (EMGE) - -51.1% - -56% -41.3% -90.2%
US Biotechs 3.5% -3.2% -2.4% 4.6% 16.3% -8.9%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • EMGE underperformed the Biotechs industry which returned 4.6% over the past year.
  • EMGE underperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

EMGE Value

 Is Emergent Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Emergent Health is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Emergent Health has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Emergent Health. This is due to cash flow or dividend data being unavailable. The share price is $0.044.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Emergent Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Emergent Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:EMGE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2014-09-30) in USD Not available
OTCPK:EMGE Share Price ** OTCPK (2020-04-08) in USD $0.04
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 16.66x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Emergent Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for Emergent Health, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Emergent Health's expected growth come at a high price?
Raw Data
OTCPK:EMGE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.84x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Emergent Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Emergent Health's assets?
Raw Data
OTCPK:EMGE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2014-09-30) in USD Not available
OTCPK:EMGE Share Price * OTCPK (2020-04-08) in USD $0.04
United States of America Biotechs Industry PB Ratio Median Figure of 432 Publicly-Listed Biotechs Companies 2.61x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x

* Primary Listing of Emergent Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PB ratio to the industry average as no data exists.

Next steps:

  1. Examine Emergent Health's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Emergent Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Emergent Health has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

EMGE Future Performance

 How is Emergent Health expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Emergent Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.9%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Emergent Health expected to grow at an attractive rate?
  • Unable to compare Emergent Health's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Emergent Health's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Emergent Health's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:EMGE Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 17.9%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:EMGE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 years ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:EMGE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2014-09-30 1 0 0
2013-12-31 1 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Emergent Health is high growth as no earnings estimate data is available.
  • Unable to determine if Emergent Health is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:EMGE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 years ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Emergent Health Company Filings, last reported 5 years ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:EMGE Past Financials Data
Date (Data in USD Millions) EPS *
2014-09-30 -0.01
2013-12-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Emergent Health will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Emergent Health's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Emergent Health's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Emergent Health's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Emergent Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Emergent Health has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

EMGE Past Performance

  How has Emergent Health performed over the past 5 years?

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Emergent Health has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data. You can see them here.

Show me the analysis anyway

  • Emergent Health's last earnings update was 1883 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Emergent Health's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient past earnings data to establish if Emergent Health's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Emergent Health's 1-year growth to the 5-year average as past earnings data has not been reported.
  • Unable to compare Emergent Health's 1-year growth to the US Biotechs industry average as past earnings data has not been reported.
Earnings and Revenue History
Emergent Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Emergent Health Company Filings, last reported 5 years ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:EMGE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2014-09-30 0.68 -0.20 0.67
2013-12-31 0.99 0.12 0.48

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Unable to establish if Emergent Health has efficiently used shareholders’ funds last year as no Return on Equity data is available.
  • Unable to establish if Emergent Health has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as past financial data has not been reported.
  • Unable to establish if Emergent Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.

Next steps:

  1. Examine Emergent Health'sEmergent Health's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Emergent Health's filings and announcements here.
  3. Past financial records are usually unavailable for companies that have just been established or recently publicly listed, which makes them inherently riskier. Take a look at a list of well-established companies here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Past performance checks
We assess Emergent Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Emergent Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

EMGE Health

 How is Emergent Health's financial health and their level of debt?

In this section we usually analyse Emergent Health's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Emergent Health has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information. You can see them here.

Show me the analysis anyway

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Emergent Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unable to compare short term assets to short term liabilities as Emergent Health has not reported sufficient balance sheet data.
  • Unable to establish if Emergent Health's long term commitments exceed its cash and other short term assets as Emergent Health has not reported sufficient balance sheet data.
Balance sheet
This treemap shows a more detailed breakdown of Emergent Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Unable to establish if Emergent Health has a high level of physical assets or inventory without balance sheet data.
  • Emergent Health has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Emergent Health Company Filings, last reported 5 years ago.

OTCPK:EMGE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2014-09-30 0.92 0.00 0.50
2013-12-31 0.96 0.00 0.81
  • Emergent Health has no debt.
  • Emergent Health has not taken on any debt in the past 5 years.
  • Emergent Health has no debt, it does not need to be covered by operating cash flow.
  • Emergent Health has no debt, therefore coverage of interest payments is not a concern.

Next steps:

  1. Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  2. Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Emergent Health's financial data was last updated here.
  3. Companies with strong financial health are considered a less risky investment. Discover these stocks here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Financial health checks
We assess Emergent Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Emergent Health has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

EMGE Dividends

 What is Emergent Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Emergent Health dividends.
If you bought $2,000 of Emergent Health shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Emergent Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Emergent Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:EMGE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 67 Stocks 2.1%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Emergent Health has not reported any payouts.
  • Unable to verify if Emergent Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Emergent Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Emergent Health has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Emergent Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Emergent Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Emergent Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

EMGE Management

 What is the CEO of Emergent Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Swenson
TENURE AS CEO 4.8 years
CEO Bio

Mr. Chris Swenson has been the Chief Executive Officer, President and Director at Emergent Health Corp since June 15, 2015. Mr. Swenson has over 25 years of financial experience. His areas of concentration include financial analysis, strategic planning, business development and budgeting. He served as Chief Financial Officer at Cenx, Inc. from 2009 to 2013. He served as Vice President of Finance at Cenx, Inc. He served as the Chief Financial Officer of Telegea, Inc. He served as Vice President of the Telecommunications and Technology Group of Fidelity Ventures. Before joining Fidelity, he served as a Senior Analyst at Tucker Anthony (now RBC). He was RBC's lead telecom analyst and was named to the Wall Street Journal's All Star Analyst list in 1994. Since 2014, he has served as the Chief Financial Officer of Neaclear , Inc. From 2001 to 2008, he served as the Vice President of Finance for Inteliquent Corp, located in Chicago, Il and engaged in Telecom Services. Mr. Swenson earned his BA from the University of New Hampshire and his MBA from Babson College.

CEO Compensation
  • Insufficient data for Chris to compare compensation growth.
  • Insufficient data for Chris to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team

John Cappello

TITLE
President & Chief Science Advisor
COMPENSATION
$82K
AGE
78

Chris Swenson

TITLE
CEO, President & Director
TENURE
4.8 yrs

Gregory McCauley

TITLE
Corporate Counsel
Board of Directors Tenure

Average tenure and age of the Emergent Health board of directors in years:

5.3
Average Tenure
66
Average Age
  • The tenure for the Emergent Health board of directors is about average.
Board of Directors

Michael Maguire

TITLE
Chairman
COMPENSATION
$1,000
AGE
55

Chris Swenson

TITLE
CEO, President & Director
TENURE
4.8 yrs

Robert McCoy

TITLE
Director
COMPENSATION
$1,000
AGE
81
TENURE
5.3 yrs

David Jones

TITLE
Director
COMPENSATION
$1,000
AGE
70
TENURE
5.3 yrs

Kevin Harrington

TITLE
Director
COMPENSATION
$9K
AGE
62
TENURE
5.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Emergent Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Emergent Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

EMGE News

Simply Wall St News

EMGE Company Info

Description

Emergent Health Corp. develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. Its products comprise Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and products for reducing facial wrinkles. The company distributes its products through health food stores, pharmacies, and various other retail outlets throughout the United States and internationally. Emergent Health Corp. is based in King of Prussia, Pennsylvania. As of August 26, 2014, Emergent Health Corp was taken private.

Details
Name: Emergent Health Corp
EMGE
Exchange: OTCPK
Founded:
$1,844,920
41,930,000
Website: http://www.emergenthealth.com
Address: Emergent Health Corp
10120 Valley Forge Circle,
Suite 257,
King of Prussia,
Pennsylvania, 19406,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK EMGE Common Stock Pink Sheets LLC US USD 07. Dec 2007
Number of employees
Current staff
Staff numbers
0
Emergent Health employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 02:19
End of day share price update: 2020/04/08 00:00
Last earnings filing: 2015/02/12
Last earnings reported: 2014/09/30
Last annual earnings reported: 2013/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.